Mechanisms and therapeutic implications of the placebo effect in neurological and psychiatric conditions.
Identifieur interne : 000D37 ( Main/Exploration ); précédent : 000D36; suivant : 000D38Mechanisms and therapeutic implications of the placebo effect in neurological and psychiatric conditions.
Auteurs : Danielle Murray [Canada] ; A Jon StoesslSource :
- Pharmacology & therapeutics [ 1879-016X ] ; 2013.
English descriptors
- KwdEn :
- MESH :
- drug therapy : Mental Disorders, Nervous System Diseases.
- pathology : Mental Disorders, Nervous System Diseases.
- Animals, Humans, Placebo Effect.
Abstract
The power of a placebo to effect clinically meaningful neurobiological change comparable to pharmacological therapies has been demonstrated, although the mechanisms are not fully understood. Predicting placebo responsiveness has only recently received more attention, but psychological disposition, contextual and biological factors are now known to dramatically affect a person's susceptibility to the placebo effect. The placebo effect depends upon expectancies that can be modified in a number of ways, including conditioning through explicit or implicit learned associations. Based on the dopaminergic response to anticipation of benefit in Parkinson's disease, it was suggested that the placebo effect can be seen as analogous to the expectation of reward. Dopaminergic pathways have since been implicated in the placebo response in pain and depression. Additionally, endogenous opioid release is known to mediate many forms of placebo analgesia. We provide an overview of the mechanisms and the therapeutic implications of the placebo effect in neurological and psychiatric conditions. We include evidence for detrimental effects arising from seemingly inert interventions, termed the 'nocebo effect.' Neuroimaging has critically advanced the study of the placebo effect and provides some of the strongest evidence for the mechanisms of this phenomenon prevalent across an array of human health-related circumstances. This review specifically focuses on mechanisms of the placebo effect in the three conditions that have most significantly demonstrated this effect and for which a plausible physiological basis can be identified: pain, PD and depression. Other neurological and psychiatric diseases reviewed include multiple sclerosis, Huntington's disease, Alzheimer's disease, schizophrenia and epilepsy.
DOI: 10.1016/j.pharmthera.2013.07.009
PubMed: 23880289
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000835
- to stream PubMed, to step Curation: 000835
- to stream PubMed, to step Checkpoint: 000835
- to stream Ncbi, to step Merge: 001515
- to stream Ncbi, to step Curation: 001515
- to stream Ncbi, to step Checkpoint: 001515
- to stream Main, to step Merge: 000D48
- to stream Main, to step Curation: 000D37
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Mechanisms and therapeutic implications of the placebo effect in neurological and psychiatric conditions.</title>
<author><name sortKey="Murray, Danielle" sort="Murray, Danielle" uniqKey="Murray D" first="Danielle" last="Murray">Danielle Murray</name>
<affiliation wicri:level="1"><nlm:affiliation>Pacific Parkinson's Research Centre and Department of Medicine, Division of Neurology, University of British Columbia & Vancouver Coastal Health, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Pacific Parkinson's Research Centre and Department of Medicine, Division of Neurology, University of British Columbia & Vancouver Coastal Health</wicri:regionArea>
<wicri:noRegion>University of British Columbia & Vancouver Coastal Health</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Stoessl, A Jon" sort="Stoessl, A Jon" uniqKey="Stoessl A" first="A Jon" last="Stoessl">A Jon Stoessl</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2013">2013</date>
<idno type="RBID">pubmed:23880289</idno>
<idno type="pmid">23880289</idno>
<idno type="doi">10.1016/j.pharmthera.2013.07.009</idno>
<idno type="wicri:Area/PubMed/Corpus">000835</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000835</idno>
<idno type="wicri:Area/PubMed/Curation">000835</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000835</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000835</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000835</idno>
<idno type="wicri:Area/Ncbi/Merge">001515</idno>
<idno type="wicri:Area/Ncbi/Curation">001515</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001515</idno>
<idno type="wicri:Area/Main/Merge">000D48</idno>
<idno type="wicri:Area/Main/Curation">000D37</idno>
<idno type="wicri:Area/Main/Exploration">000D37</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Mechanisms and therapeutic implications of the placebo effect in neurological and psychiatric conditions.</title>
<author><name sortKey="Murray, Danielle" sort="Murray, Danielle" uniqKey="Murray D" first="Danielle" last="Murray">Danielle Murray</name>
<affiliation wicri:level="1"><nlm:affiliation>Pacific Parkinson's Research Centre and Department of Medicine, Division of Neurology, University of British Columbia & Vancouver Coastal Health, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Pacific Parkinson's Research Centre and Department of Medicine, Division of Neurology, University of British Columbia & Vancouver Coastal Health</wicri:regionArea>
<wicri:noRegion>University of British Columbia & Vancouver Coastal Health</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Stoessl, A Jon" sort="Stoessl, A Jon" uniqKey="Stoessl A" first="A Jon" last="Stoessl">A Jon Stoessl</name>
</author>
</analytic>
<series><title level="j">Pharmacology & therapeutics</title>
<idno type="eISSN">1879-016X</idno>
<imprint><date when="2013" type="published">2013</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Humans</term>
<term>Mental Disorders (drug therapy)</term>
<term>Mental Disorders (pathology)</term>
<term>Nervous System Diseases (drug therapy)</term>
<term>Nervous System Diseases (pathology)</term>
<term>Placebo Effect</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Mental Disorders</term>
<term>Nervous System Diseases</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Mental Disorders</term>
<term>Nervous System Diseases</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Humans</term>
<term>Placebo Effect</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The power of a placebo to effect clinically meaningful neurobiological change comparable to pharmacological therapies has been demonstrated, although the mechanisms are not fully understood. Predicting placebo responsiveness has only recently received more attention, but psychological disposition, contextual and biological factors are now known to dramatically affect a person's susceptibility to the placebo effect. The placebo effect depends upon expectancies that can be modified in a number of ways, including conditioning through explicit or implicit learned associations. Based on the dopaminergic response to anticipation of benefit in Parkinson's disease, it was suggested that the placebo effect can be seen as analogous to the expectation of reward. Dopaminergic pathways have since been implicated in the placebo response in pain and depression. Additionally, endogenous opioid release is known to mediate many forms of placebo analgesia. We provide an overview of the mechanisms and the therapeutic implications of the placebo effect in neurological and psychiatric conditions. We include evidence for detrimental effects arising from seemingly inert interventions, termed the 'nocebo effect.' Neuroimaging has critically advanced the study of the placebo effect and provides some of the strongest evidence for the mechanisms of this phenomenon prevalent across an array of human health-related circumstances. This review specifically focuses on mechanisms of the placebo effect in the three conditions that have most significantly demonstrated this effect and for which a plausible physiological basis can be identified: pain, PD and depression. Other neurological and psychiatric diseases reviewed include multiple sclerosis, Huntington's disease, Alzheimer's disease, schizophrenia and epilepsy.</div>
</front>
</TEI>
<affiliations><list><country><li>Canada</li>
</country>
</list>
<tree><noCountry><name sortKey="Stoessl, A Jon" sort="Stoessl, A Jon" uniqKey="Stoessl A" first="A Jon" last="Stoessl">A Jon Stoessl</name>
</noCountry>
<country name="Canada"><noRegion><name sortKey="Murray, Danielle" sort="Murray, Danielle" uniqKey="Murray D" first="Danielle" last="Murray">Danielle Murray</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000D37 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000D37 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Canada |area= ParkinsonCanadaV1 |flux= Main |étape= Exploration |type= RBID |clé= pubmed:23880289 |texte= Mechanisms and therapeutic implications of the placebo effect in neurological and psychiatric conditions. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:23880289" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \ | NlmPubMed2Wicri -a ParkinsonCanadaV1
This area was generated with Dilib version V0.6.29. |